ACTN4 and lung adenocarcinoma: We recently demonstrated that patients with gene amplification of ACTN4 in stage-I lung adenocarcinoma who never underwent ADJ with any drug definitely have a worse prognosis than patients without gene amplification of ACTN4, and we reported the potential clinical applicability of ACTN4 as a prognostic biomarker of stage-I adenocarcinoma [10].